Gemini — The in silico Patient™

Gemini — The in silico Patient™ simulates disease progression and drug response at the individualized patient level. Powered by large clinico-genomic patient data and REFS causal AI and simulation technology, Gemini reconstructs the complex molecular mechanisms driving outcomes.

Gemini enables better clinical trial design, including identification of responder/non-responder subpopulations and underlying mechanisms, in addition to generating evidence for line of therapy changes and treatment sequence optimization.

Gemini is also being leveraged to discover novel disease mechanisms and drug targets, leading to the discovery of new drugs across various diseases.

To speak to someone about our AI-powered simulation platform, fill out the form and someone from our team will be in touch shortly.


In the meantime, if you need immediate assistance, email